Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab for optic neuritis associated with neuromyelitis optica spectrum disorder
ChiCTR2400086835Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ofatumumab in optic neuritis (ON) and Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chinese PLA General Hospital. Primary endpoint: Annualized relapse rate (ARR). Started Jul 2024; status: recruiting.
02
Drugs
ofatumumab
03
Conditions
optic neuritis (ON)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2400086835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086835.